NPPB and hydrops fetalis: Following the recently published single-arm, multicenter PROACTIVE-HF trial,the CordellaTM HF system received FDA approval for patients with NYHA ClassIII symptoms and elevated serum NT-proBNP levels or HF-related hospitalizationwithin the preceding 12 months, independent of LVEF [18].